WO2001098333A3 - Modification of hepatitis b core antigen - Google Patents

Modification of hepatitis b core antigen Download PDF

Info

Publication number
WO2001098333A3
WO2001098333A3 PCT/GB2001/002817 GB0102817W WO0198333A3 WO 2001098333 A3 WO2001098333 A3 WO 2001098333A3 GB 0102817 W GB0102817 W GB 0102817W WO 0198333 A3 WO0198333 A3 WO 0198333A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
hbcag
protein
core antigen
modification
Prior art date
Application number
PCT/GB2001/002817
Other languages
French (fr)
Other versions
WO2001098333A2 (en
Inventor
Mark Page
Jing-Li Li
Paul Pumpens
Galina Borisova
Original Assignee
Celltech Pharmaceuticals Ltd
Mark Page
Li Jing Li
Paul Pumpens
Galina Borisova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0015308A external-priority patent/GB0015308D0/en
Priority claimed from GB0024544A external-priority patent/GB0024544D0/en
Application filed by Celltech Pharmaceuticals Ltd, Mark Page, Li Jing Li, Paul Pumpens, Galina Borisova filed Critical Celltech Pharmaceuticals Ltd
Priority to US10/312,045 priority Critical patent/US20040054139A1/en
Priority to AU6616301A priority patent/AU6616301A/en
Priority to AU2001266163A priority patent/AU2001266163B2/en
Priority to CA2413546A priority patent/CA2413546C/en
Priority to JP2002504288A priority patent/JP2004500868A/en
Priority to EP01943625A priority patent/EP1294893B1/en
Priority to DE60117978T priority patent/DE60117978T2/en
Publication of WO2001098333A2 publication Critical patent/WO2001098333A2/en
Publication of WO2001098333A3 publication Critical patent/WO2001098333A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A protein is provided comprising hepatitis B core antigen (HBcAg) wherein one or more of the four arginine repeats has been deleted, said protein comprising the C-terminal cysteine of HBcAg. The deleted region may be replaced by an epitope from a protein other than HBcAg, in which case the HBcAg acts as a carrier to present the epitope to the immune system. The chimeric protein is useful in prophylactic and therapeutic vaccination of a host, for example against hepatitis B virus.
PCT/GB2001/002817 2000-06-22 2001-06-22 Modification of hepatitis b core antigen WO2001098333A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US10/312,045 US20040054139A1 (en) 2000-06-22 2001-06-22 Modification of hepatitis b core antigen
AU6616301A AU6616301A (en) 2000-06-22 2001-06-22 Modification of hepatitis b core antigen
AU2001266163A AU2001266163B2 (en) 2000-06-22 2001-06-22 Modification of hepatitis b core antigen
CA2413546A CA2413546C (en) 2000-06-22 2001-06-22 Modification of hepatitis b core antigen
JP2002504288A JP2004500868A (en) 2000-06-22 2001-06-22 Modification of hepatitis B core antigen
EP01943625A EP1294893B1 (en) 2000-06-22 2001-06-22 Modification of hepatitis b core antigen
DE60117978T DE60117978T2 (en) 2000-06-22 2001-06-22 MODIFYING THE HEPATITIS B NUCLEAR ANIMAL

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0015308A GB0015308D0 (en) 2000-06-22 2000-06-22 Modification of hepatitis B core antigen
GB0015308.0 2000-06-22
GB0024544A GB0024544D0 (en) 2000-10-06 2000-10-06 Modification of hepatitus B core antigen
GB0024544.9 2000-10-06

Publications (2)

Publication Number Publication Date
WO2001098333A2 WO2001098333A2 (en) 2001-12-27
WO2001098333A3 true WO2001098333A3 (en) 2002-03-28

Family

ID=26244528

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/002817 WO2001098333A2 (en) 2000-06-22 2001-06-22 Modification of hepatitis b core antigen

Country Status (11)

Country Link
US (1) US20040054139A1 (en)
EP (1) EP1294893B1 (en)
JP (1) JP2004500868A (en)
AT (1) ATE320493T1 (en)
AU (2) AU6616301A (en)
CA (1) CA2413546C (en)
DE (1) DE60117978T2 (en)
DK (1) DK1294893T3 (en)
ES (1) ES2260235T3 (en)
PT (1) PT1294893E (en)
WO (1) WO2001098333A2 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1218514B1 (en) * 1999-10-08 2006-04-26 Celltech Pharma Europe Limited Designing immunogens
EP1268530B1 (en) * 2000-04-07 2006-08-16 University Of Leeds Hepatitis b core antigen fusion proteins
US6942866B2 (en) 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
CU23002A1 (en) * 2000-12-01 2004-11-18 Ct Ingenieria Genetica Biotech METHOD OF OBTAINING ANTIGENIC AGGREGATES AND THEIR USE IN FORMULATIONS
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US20030202982A1 (en) * 2001-08-15 2003-10-30 Birkett Ashley J. Influenza immunogen and vaccine
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US20040146524A1 (en) * 2002-02-21 2004-07-29 Katelynne Lyons Stabilized immunogenic HBc chimer particles
CN1599623B (en) 2001-09-14 2011-05-11 赛托斯生物技术公司 Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
MXPA04002644A (en) 2001-10-05 2004-07-08 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof.
AU2003215395A1 (en) * 2002-02-21 2003-09-09 Apovia, Inc. STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
KR20120041739A (en) 2002-07-18 2012-05-02 사이토스 바이오테크놀로지 아게 Hapten-carrier conjugates and uses thereof
DE60336902D1 (en) 2002-07-19 2011-06-09 Cytos Biotechnology Ag VACCINE COMPOSITIONS CONTAINING AMYLOID BETA 1-6 ANTIGENARRAYS
WO2004085635A1 (en) 2003-03-26 2004-10-07 Cytos Biotechnology Ag Melan-a peptide analogue-virus-like-particle conjugates
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
US7144712B2 (en) * 2003-07-30 2006-12-05 Vaccine Research Institute Of San Diego Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof
WO2005011571A2 (en) 2003-07-30 2005-02-10 Vaccine Research Institute Of San Diego Hepatitis virus core proteins as vaccine platforms and methods of use thereof
US7320795B2 (en) 2003-07-30 2008-01-22 Vaccine Research Institute Of San Diego Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof
CN1925843A (en) * 2003-12-02 2007-03-07 细胞免疫科学公司 Methods and compositions for the production of monoclonal antibodies
EP1764369A1 (en) 2005-09-16 2007-03-21 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vaccines comprising truncated HBC core protein plus saponin-based adjuvant
EP2219458B1 (en) 2007-11-08 2015-07-15 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
AU2009325950B2 (en) 2008-12-09 2013-03-07 Pfizer Vaccines Llc IgE CH3 peptide vaccine
RU2518291C2 (en) 2009-07-30 2014-06-10 Пфайзер Вэксинс ЭлЭлСи Antigen tau-peptides and their application
CA2771770A1 (en) 2009-09-03 2011-03-10 Pfizer Vaccines Llc Pcsk9 vaccine
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
EP2698164B1 (en) * 2011-04-15 2018-04-04 Osaka University Dna vaccine
CN104768575B (en) 2012-08-31 2017-09-08 国立大学法人大阪大学 DNA vaccination containing VEGF specificity epitopes and/or ANG2 specificity epitope
JP6001974B2 (en) 2012-09-21 2016-10-05 アンジェスＭｇ株式会社 DNA vaccine containing a specific epitope of apolipoprotein (a)
CN104341506A (en) * 2013-07-30 2015-02-11 复旦大学 Recombinant fusion protein and use thereof
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
WO2015133467A1 (en) * 2014-03-06 2015-09-11 株式会社シノテスト Vaccine against hepatitis c virus, and diagnostic hbc/hcv e2 peptide chimeric protein
KR20200128703A (en) * 2018-03-06 2020-11-16 프레시전 인코포레이티드 Hepatitis B vaccine and uses thereof
CN114729010A (en) * 2019-08-29 2022-07-08 维尔生物科技有限公司 Hepatitis B virus vaccine
WO2021067181A1 (en) 2019-09-30 2021-04-08 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0421635A1 (en) * 1989-09-19 1991-04-10 The Wellcome Foundation Limited Chimaeric hepadnavirus core antigen proteins
WO2000026385A1 (en) * 1998-11-05 2000-05-11 Powderject Vaccines, Inc. Nucleic acid constructs for genetic immunization

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0421635A1 (en) * 1989-09-19 1991-04-10 The Wellcome Foundation Limited Chimaeric hepadnavirus core antigen proteins
WO2000026385A1 (en) * 1998-11-05 2000-05-11 Powderject Vaccines, Inc. Nucleic acid constructs for genetic immunization

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BORISOVA G P ET AL: "RECOMBINANT CORE PARTICLES OF HEPATITIS B VIRUS EXPOSING FOREIGN ANTIGENIC DETERMINANTS ON THEIR SURFACE", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 259, no. 1, 1 December 1989 (1989-12-01), pages 121 - 124, XP002035980, ISSN: 0014-5793 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1992, ZHOU S ET AL: "CYS RESIDUES OF THE HEPATITIS B VIRUS CAPSID PROTEIN ARE NOT ESSENTIAL FOR THE ASSEMBLY OF VIRAL CORE PARTICLES BUT CAN INFLUENCE THEIR STABILITY", XP002185073, Database accession no. PREV199294115400 *
HATTON T ET AL: "RNA AND DNA-BINDING ACTIVITIES IN HEPATITIS B VIRUS CAPSID PROTEIN A MODEL FOR THEIR ROLES IN VIRAL REPLICATION", JOURNAL OF VIROLOGY, vol. 66, no. 9, 1992, pages 5232 - 5241, XP001041852, ISSN: 0022-538X *
HUI ERIC KA-WAI ET AL: "Hepatitis B virus maturation is affected by the incorporation of core proteins having a C-terminal substitution of arginine or lysine stretches.", JOURNAL OF GENERAL VIROLOGY, vol. 80, no. 10, October 1999 (1999-10-01), pages 2661 - 2671, XP002185072, ISSN: 0022-1317 *
JOURNAL OF VIROLOGY, vol. 66, no. 9, 1992, pages 5393 - 5398, ISSN: 0022-538X *
SCHOEDEL F ET AL: "HYBRID HEPATITIS B VIRUS CORE ANTIGEN AS A VACCINE CARRIER MOIETY: I. PRESENTATION OF FOREIGN EPITOPES", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 44, no. 1/3, January 1996 (1996-01-01), pages 91 - 96, XP000891474, ISSN: 0168-1656 *

Also Published As

Publication number Publication date
DK1294893T3 (en) 2006-07-03
AU2001266163B2 (en) 2006-07-13
ATE320493T1 (en) 2006-04-15
EP1294893A2 (en) 2003-03-26
US20040054139A1 (en) 2004-03-18
PT1294893E (en) 2006-08-31
WO2001098333A2 (en) 2001-12-27
ES2260235T3 (en) 2006-11-01
CA2413546C (en) 2011-06-14
DE60117978T2 (en) 2006-11-02
JP2004500868A (en) 2004-01-15
DE60117978D1 (en) 2006-05-11
AU6616301A (en) 2002-01-02
CA2413546A1 (en) 2001-12-27
EP1294893B1 (en) 2006-03-15

Similar Documents

Publication Publication Date Title
WO2001098333A3 (en) Modification of hepatitis b core antigen
WO1993000365A3 (en) Hepatitis c virus (hcv) polypeptides
WO2002074795A3 (en) Oligomeric complexes of chimeric proteins with enhanced immunogenic potential
NZ545048A (en) Chimeric antigens for breaking host tolerance to foreign antigens
EP1200109A4 (en) Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
NZ512056A (en) HBV core antigen particles with multiple immunogenic components attached via peptide ligands
WO2001037869A9 (en) Vaccine compositions
WO1999057289A3 (en) INHIBIN-HBc FUSION PROTEIN
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
PT1283887E (en) Chimeric arterivirus-like particles
ATE323758T1 (en) LIVE ATTENUATE VACCINES
WO2004004761A3 (en) Adjuvant viral particle
MY128999A (en) Purification of hbv antigens for use in vaccines
WO2005004910A3 (en) Hcv vaccines
SG144692A1 (en) Antigenic proteins of shrimp white spot syndrome virus and uses thereof
AU2001246331A1 (en) Hepatitis b virus (hbv) antigenic polypeptide-heat shock protein complex and use thereof
DK1035133T3 (en) Fusion proteins comprising carriers that can induce a dual immune response
IL141443A0 (en) Vaccine comprising cytokine-induced heat shock proteins (hsp)
WO2001027282A8 (en) Plant virus particles with exogenous internal eitopes
EP1274851A4 (en) A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus orf2, and an antigenic polypeptide
WO2001049712A3 (en) Vaccine against isav (infectious salmon anaemia virus)
WO2002051237A3 (en) Helicobacter proteins, nucleic acids and uses thereof
WO2001092311A3 (en) Convergent combinatory peptide libraries and their use for vaccination against hepatitis c virus
RU2004104357A (en) VACCINE COMPOSITION POTENTIATED BY COMBINATION OF DNA AND ANTIGEN
HUP0003511A2 (en) Hepatitis b virus polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2002 504288

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001266163

Country of ref document: AU

Ref document number: 2413546

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001943625

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10312045

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001943625

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2001943625

Country of ref document: EP